Joseph Kim, MD, MPH, MBA, FACHE
@DrJosephKim
Followers
25K
Following
1K
Media
120
Statuses
13K
President of Q Synthesis LLC #CME #CE #QualityImprovement #interprofessional #education #oncology #healthcare #systemsthinking #FACHE #CPHQ #FACEHP
USA
Joined August 2008
What do you know about pan-tumor #HER2 testing? Check out this Tweetorial on this topic: https://t.co/OlX9eZW5vo and claim CME #PathTwitter #pathx #pantumor
1/18 This #CME Tweetorial is provided by @ASCP_Chicago and covers pan-tumor HER2 testing. Claim your CME credit here: https://t.co/FQ4r4QNXSU This CME activity is supported by educational grants from @AstraZeneca and @DaiichiSankyoUS
#HER2 #PathTwitter #pathx #pantumor
0
2
4
People with advanced or metastatic cancer have significant unmet needs. Our joint standards and recommendations w/ @CancerCareMASCC aim to improve quality of survivorship care. Clinicians can take immediate steps to address these needs: https://t.co/slDh1Wqd2G
#ASCOEdBook
2
21
35
Happening TMRW‼️ Don’t miss this FREE #CME webinar on how digital #pathology + AI are transforming cancer diagnostics. 🩺Presented by @DrBuiPathology 🗓️May 29 | ⏰12 PM ET 🔗Register: https://t.co/Bpzq7aPHFz
0
2
3
Just 2️⃣ days away! Please join me for a FREE #CME webinar on how AI + digital #pathology are transforming cancer diagnostics. Get the tools & insights in precision pathology. 🗓️May 29 | ⏰12 PM ET. Register now: https://t.co/LvfVhjWoSx
@TheUSCAP @dpatweet @CAPA_comm @SIIM_Tweets
0
1
3
FDA grants accelerated approval to zanidatamab-hrii for previously treated unresectable or metastatic HER2-positive biliary tract cancer #HER2
https://t.co/NPNCxIgd8U
fda.gov
On November 20, 2024, the FDA granted accelerated approval to zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals, Inc.) for biliary tract cancer.
0
1
0
Join us on Nov 26 at 12 p.m. ET for a #CME webinar on Cancer Diagnostics and Precision Medicine. This is the FIRST CME session in our new Precision Medicine Academy webinar series! Don't miss out on this insightful session! Register now: https://t.co/qBPdvlLgWi
0
1
0
13/18 Liquid biopsy (circulating tumor DNA or ctDNA) can detect HER2 amplification and mutations. ctDNA also called cell-free DNA or cfDNA. https://t.co/LuRV9JR94b
#HER2 #PathTwitter #pathx #pantumor
1
1
5
#AHRQ has released a NOFO to establish State-based Healthcare Extension Cooperatives, accelerating patient-centered outcome #research (PCOR) implementation. Two related NOFOs for a National Coordinating Center and Evaluation Center are also available. https://t.co/tZxMnO7Snb
0
1
1
A fantastic presentation by @Joshua_Reuss on adjuvant and neoadjuvant treatment options for lung tumors with actionable genomic alterations #FoxChaseLumgCME
0
4
18
ASCP is seeking #KnowledgeLab Education Program topic suggestions from our members regarding the most critical topics of interest in laboratory management, leadership, and education! Submit your topic suggestions by 10/15 for your chance to contribute to the 2025 conference!
0
3
5
What do you know about pan-tumor #HER2 testing? Check out this Tweetorial on this topic: https://t.co/OlX9eZW5vo and claim CME #PathTwitter #pathx #pantumor
1/18 This #CME Tweetorial is provided by @ASCP_Chicago and covers pan-tumor HER2 testing. Claim your CME credit here: https://t.co/FQ4r4QNXSU This CME activity is supported by educational grants from @AstraZeneca and @DaiichiSankyoUS
#HER2 #PathTwitter #pathx #pantumor
0
2
4
Memorable ‘debate’ w/ @lauren_henke on future role of the MD and team, clinical trials, and indications for online adaptive radiotherapy @ASTRO_org #ASTRO24 ending appropriately in a tie 😀by Ethos users group (smart group)! Excited to see what the future holds!
0
7
40
SMADIE is accepting proposals for the 6th Annual Conference on Disability in Healthcare and Medicine, scheduled for April 26, 2025! Link to online form to submit your proposal: https://t.co/nMCBJnryUh
#HealthcareConference #StanfordMedicine #SMADIE
0
7
11
11/18 Variations in tissue fixation and IHC processing protocols may impact HER2 test results. Assay validation and ongoing monitoring are essential. #HER2 #PathTwitter #pathx #pantumor
1
1
3
6
22
166
🎙@fumikochino of @MDAndersonNews and @ROsarogiagbon of @BaptistHealth discuss key takeaways from #ASCOQLTY24 on the latest episode of the #ASCODailyNews Podcast: https://t.co/Xwjj1zXZsR
#OncTwitter
0
4
14
8/18 Tumor heterogeneity can make HER2 interpretation challenging. Here’s an example of intratumoral HER2 heterogeneity. https://t.co/Cig40jNdv0
#HER2 #PathTwitter #pathx #pantumor
pmc.ncbi.nlm.nih.gov
Human epidermal growth factor receptor 2 (HER2) protein overexpression and/or HER2 gene amplification is found in about 20% of invasive breast cancers. It is a sole predictive marker for treatment...
1
1
3
10/18 HER2 scoring criteria for gastric and GE cancers were published in 2016. Note the differences for biopsy vs. surgical specimens. https://t.co/97xeDbDoHV
#HER2 #PathTwitter #pathx #pantumor
1
1
3
7/18 Examples of HER2 staining using different IHC platforms and antibodies. https://t.co/ImGLKlmjqV
#HER2 #PathTwitter #pathx #pantumor
1
1
3
In case you missed this, here's a CME Tweetorial from @ASCP_Chicago on #HER2 testing across different gynecologic tumors #pantumor #tumoragnostic
https://t.co/JMcOZLrNIs and don't forget to claim #CME #PathTwitter #biomarkers #PathX #ovariancancer #cervicalcancer
This #CME Tweetorial is provided by @ASCP_Chicago and covers HER2 testing in advanced gynecologic cancers. Claim your CME credit here: https://t.co/fLFjXx0Gur This CME activity is supported by educational grants from @AstraZeneca and @DaiichiSankyoUS
#HER2 #PathTwitter #GYNPATH
0
2
2